查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1702371

全球左心室辅助装置（LVAD）市场 - 2025-2033

Global Left Ventricular Assist Device (LVAD) Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球左心室辅助装置 (LVAD) 市场规模达到 13.1 亿美元，预计到 2033 年将达到 26.7 亿美元，在 2025-2033 年预测期内的复合年增长率为 8.3%。

左心室辅助装置 (LVAD) 是一种机械泵，当负责向全身泵送含氧血液的左心室过于虚弱而无法自行完成工作时，用于支持患者心臟的功能。 LVAD 通常用于患有严重心臟衰竭的患者，特别是那些无法透过药物或其他疗法控制病情的患者。

LVAD 通常被用作等待心臟移植的患者的临时解决方案，特别是当他们的心臟功能恶化到没有机械支持就无法等待的程度时。对于不适合进行心臟移植的患者（由于年龄、合併症或其他因素），LVAD 可以作为治疗严重心臟衰竭的长期或永久解决方案（目标疗法）。

市场动态：

驾驶员和约束装置

LVAD 技术的不断进步极大地推动了左心室辅助装置市场的成长。

从脉动流 LVAD 到持续流 LVAD 的转变彻底改变了 LVAD 技术。与脉动流装置相比，连续流装置更可靠，零件更少，且不易发生机械故障。例如，HeartMate 3 LVAD（雅培）是一种持续流动装置，已显示出对患者治疗效果的显着改善。临床试验发现，与使用旧式脉动流装置的患者相比，使用 HeartMate 3 的患者存活率更高且併发症更少。

LVAD 的小型化导致了更小、更有效率的设备的开发。这些设备更容易植入，所需的侵入性更小，并且能为患者提供更好的活动能力。生物相容性材料的改善显着减少了感染和凝血等併发症。现代 LVAD 采用先进的血液接触材料，最大限度地降低血栓形成（血块）的风险，从而改善患者的治疗效果。技术进步带来了更好的密封技术和改进的传动系统设计，降低了感染和设备故障的风险。

手术植入的复杂性阻碍了市场的成长

虽然左心室辅助装置 (LVAD) 已被证明是挽救末期心臟衰竭患者生命的解决方案，但其手术植入的复杂性仍然是这些装置更广泛应用的重大障碍。植入过程涉及高度复杂的手术并带来多种风险，这使得扩大 LVAD 的使用成为一个挑战，特别是在资源受限或专业化程度较低的医疗保健环境中。

LVAD 植入是一项高度复杂的手术，需要大量专业知识，因为它涉及将设备连接到心臟和循环系统。由于该手术的侵入性，感染、出血、血栓形成（血块）和设备故障等併发症的风险很高。

併发症的高风险会增加患者的发病率和住院时间，使得患者和医疗保健提供者在选择 LVAD 植入时更加谨慎。这反过来又限制了 LVAD 的采用，尤其是对于健康状况已经很脆弱且患有其他合併症的患者。 LVAD 植入后的恢復过程很长，需要持续监测感染、出血或帮浦故障等併发症。患者还需要遵循严格的术后治疗方案，包括抗凝血治疗，以防止血栓。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的程式码片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • LVAD 技术的不断进步
      • 心臟衰竭盛行率不断上升
    • 限制
      • 手术植入的复杂性
      • 设备拒绝和不相容的风险
    • 机会
      • 小型化和下一代 LVAD
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大行销品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：左心室辅助装置 (LVAD) 市场（依产品类型）

  • 持续流 LVAD
  • 脉动流左心室辅助装置

第六章：左心室辅助装置（LVAD）市场（依应用）

  • 移植桥樑（BTT）
  • 目的地疗法（DT）
  • 復苏之桥（BTR）

第 7 章：左心室辅助装置 (LVAD) 市场（依最终用户）

  • 医院
  • 心臟专科诊所
  • 门诊手术中心
  • 其他的

第 8 章：左心室辅助装置 (LVAD) 市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Abbott
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • CorWave SA
  • Berlin Heart
  • LivaNova, Inc.
  • Evaheart, Inc.
  • BrioHealth Solutions

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD2890

The global left ventricular assist device (LVAD) market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.67 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

A Left Ventricular Assist Device (LVAD) is a mechanical pump used to support the function of a patient's heart when the left ventricle, responsible for pumping oxygenated blood throughout the body, is too weak to do so on its own. LVADs are typically used in patients with severe heart failure, particularly those whose condition cannot be managed by medication or other therapies.

LVADs are often used as a temporary solution for patients awaiting a heart transplant, especially when their heart function has deteriorated to a point where they cannot wait without mechanical support. For patients who are not candidates for a heart transplant (due to age, comorbidities, or other factors), LVADs can serve as a long-term or permanent solution (destination therapy) to manage severe heart failure.

Market Dynamics: Drivers & Restraints

Rising advancements in LVAD technology are significantly driving the left ventricular assist device market growth.

The shift from pulsatile-flow LVADs to continuous-flow LVADs has been a game-changer in LVAD technology. Continuous-flow devices are more reliable, have fewer parts, and are less prone to mechanical failure compared to pulsatile-flow devices. For instance, the HeartMate 3 LVAD (Abbott), a continuous-flow device, has shown significant improvement in patient outcomes. In clinical trials, it was found that patients with HeartMate 3 experienced better survival rates and fewer complications compared to those with older pulsatile-flow devices.

Miniaturization of LVADs has led to the development of smaller, more efficient devices. These devices are easier to implant, require less invasive procedures, and offer better mobility for patients. Improvements in biocompatible materials have significantly reduced complications like infection and clotting. Modern LVADs use advanced blood-contact materials that minimize the risk of thrombosis (blood clots), leading to better patient outcomes. Technological improvements have led to better sealing technologies and improved driveline designs, reducing the risk of infections and device malfunctions.

Complexity of surgical implantation is hampering the market growth

While left ventricular assist devices (LVADs) have proven to be life-saving solutions for patients with end-stage heart failure, their surgical implantation complexity remains a significant barrier to the broader adoption of these devices. The implantation process involves highly intricate surgeries and poses several risks, making it a challenge to scale the use of LVADs, particularly in resource-constrained or less-specialized healthcare settings.

LVAD implantation is a highly complex surgery that requires significant expertise as it involves connecting the device to both the heart and the circulatory system. Due to the invasive nature of the procedure, there is a high risk of complications such as infection, bleeding, thrombosis (blood clots), and device malfunctions.

The high risk of complications increases patient morbidity and hospitalization time, making both patients and healthcare providers more cautious about opting for LVAD implantation. This, in turn, limits the adoption of LVADs, especially in patients with additional comorbidities who are already in a fragile state of health. The recovery process following LVAD implantation is lengthy and requires constant monitoring for complications like infection, bleeding, or pump malfunction. Patients also need to follow a strict post-operative regimen, including anticoagulation therapy, to prevent blood clots.

Segment Analysis

The global left ventricular assist device (LVAD) market is segmented based on product type, application, end-user, and region.

Product Type:

The continuous flow LVAD segment is expected to dominate the left ventricular assist device market with the highest market share.

The continuous flow left ventricular assist device is the dominant segment within the LVAD market due to its superior performance, improved patient outcomes, and advancements in technology. Unlike traditional pulsatile-flow LVADs, which mimic the heart's natural pumping action, continuous-flow LVADs provide a steady, continuous flow of blood, offering several advantages that contribute to their growing adoption and market dominance.

Continuous flow LVADs offer better clinical outcomes compared to pulsatile flow devices, particularly in terms of survival rates, reduced complication risks, and long-term device performance. For instance, the HeartMate 3 LVAD, a continuous flow device from Abbott, has shown outstanding results in clinical trials. In the MOMENTUM 3 study, the HeartMate 3 demonstrated an 82.8% survival rate at two years, a significant improvement over the pulsatile flow HeartMate II.

Continuous flow LVADs are more compact and efficient than pulsatile devices, offering significant benefits in terms of device size, weight, and reliability. Continuous flow devices typically have a longer operational life and fewer moving parts, which reduces the likelihood of mechanical failure. As a result, patients with continuous flow LVADs often experience more consistent heart function and better quality of life. Continuous flow LVADs have been shown to carry a lower risk of complications such as pump thrombosis, stroke, and infection, which are often associated with pulsatile devices.

Geographical Analysis

North America is expected to hold a significant position in the global left ventricular assist device market with the highest market share

North America, particularly the United States and Canada, is the leading region in the LVAD market due to its strong healthcare infrastructure, high prevalence of heart failure, advanced medical technology, regulatory approvals, and favorable reimbursement policies. The region accounts for the largest market share globally, with significant contributions from key players like Abbott, Medtronic, and others.

The growing number of heart failure (HF) cases in North America is a major factor driving LVAD adoption. For instance, according to the National Institute of Health (NIH), approximately 6.7 million Americans over 20 years of age have HF, and the prevalence is expected to rise to 8.5 million Americans by 2030. The lifetime risk of HF has increased to 24%; approximately 1 in 4 persons will develop HF in their lifetime. The increasing number of patients with end-stage heart failure has led to a higher demand for LVADs as both Bridge-to-Transplant (BTT) and Destination Therapy (DT).

North America is home to leading LVAD manufacturers, which contribute to rapid product innovations and market growth. For instance, Abbott's HeartMate 3, a continuous flow LVAD, has become the gold standard in mechanical circulatory support.

Competitive Landscape

Top companies in the left ventricular assist device (LVAD) market include Abbott, CorWave SA, Berlin Heart, LivaNova, Inc., Evaheart, Inc., and BrioHealth Solutions, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global left ventricular assist device (LVAD) market report delivers a detailed analysis with 50 key tables, more than 48 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in LVAD Technology
      • 3.1.1.2. Increasing Prevalence of Heart Failure
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Surgical Implantation
      • 3.1.2.2. Risk of Device Rejection and Incompatibility
    • 3.1.3. Opportunity
      • 3.1.3.1. Miniaturization and Next-Generation LVADs
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Left Ventricular Assist Device (LVAD) Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Continuous Flow LVAD*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Pulsatile Flow LVAD

6. Left Ventricular Assist Device (LVAD) Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Bridge to Transplant (BTT)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Destination Therapy (DT)
  • 6.4. Bridge to Recovery (BTR)

7. Left Ventricular Assist Device (LVAD) Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Cardiac Clinics
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. Left Ventricular Assist Device (LVAD) Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. CorWave SA
  • 10.3. Berlin Heart
  • 10.4. LivaNova, Inc.
  • 10.5. Evaheart, Inc.
  • 10.6. BrioHealth Solutions

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us